Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
February 02 2023 - 7:41PM
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global
biopharmaceutical company developing novel oral small molecule
therapeutics for metabolic and pulmonary diseases, today announced
the pricing of its upsized initial public offering of 10,740,000
American depositary shares (ADSs), each representing three ordinary
shares, at a public offering price of $15.00 per ADS. The aggregate
gross proceeds to Structure Therapeutics from the offering are
expected to be $161.1 million before deducting underwriting
discounts and commissions and offering expenses. In addition,
Structure Therapeutics has granted the underwriters a 30-day option
to purchase up to an additional 1,611,000 ADSs at the initial
public offering price, less underwriting discounts and commissions.
All of the ADSs are being offered by Structure Therapeutics. The
shares are expected to begin trading on the Nasdaq Global Market on
February 3, 2023 under the ticker symbol “GPCR.” The offering is
expected to close on February 7, 2023, subject to the satisfaction
of customary closing conditions.
Jefferies, SVB Securities, Guggenheim Securities, and BMO
Capital Markets are acting as joint book-running managers for the
offering.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission and became
effective on February 2, 2023. The offering is being made only by
means of a written prospectus. A copy of the final prospectus
relating to the offering, when available, may be obtained from:
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, telephone: (877) 821-7388,
email: Prospectus_Department@Jefferies.com; SVB Securities LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, email:
syndicate@svbsecurities.com; Guggenheim Securities, LLC, Attention:
Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY
10017, telephone: (212) 518-9544, email:
GSEquityProspectusDelivery@guggenheimpartners.com; or BMO Capital
Markets Corp., Attention: Equity Syndicate Department, 151 W 42nd
Street, 32nd Floor New York, NY 10036, telephone: (800) 414-3627,
email: bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Structure TherapeuticsStructure
Therapeutics is a clinical-stage global biopharmaceutical company
discovering and developing novel oral therapeutics to treat chronic
metabolic and pulmonary diseases with unmet medical needs. By
leveraging its next generation structure-based drug discovery
platform, the company has built a pipeline including two
clinical-stage small molecule compounds designed to overcome the
limitations of biologics and peptide therapies. The company is
currently focused on the GPCR family of drug targets.
Contacts:
Investor Relations:Jun Yoon, Chief Financial
OfficerStructure Therapeutics Inc.ir@structuretx.com
Structure Therapeutics (NASDAQ:GPCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Structure Therapeutics (NASDAQ:GPCR)
Historical Stock Chart
From Sep 2023 to Sep 2024